Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Sangamo Therapeutics
Biotech
Sangamo enters bankruptcy, reveals asset sales with 2 pharmas
Eli Lilly and Astellas have emerged as “stalking horse bidders” for certain assets as part of Sangamo’s bankruptcy process.
Eric Sagonowsky
Jun 23, 2026 10:57am
Cash-strapped Sangamo seeks partner for new gene therapy
Jun 24, 2025 11:53am
Lilly saves gene therapy biotech with $18M upfront deal
Apr 3, 2025 6:00pm
Pfizer crashes Sangamo's stock by ending hem A gene therapy pact
Jan 2, 2025 6:08am
Astellas pays Sangamo $20M to boost neurological gene therapies
Dec 19, 2024 7:13am
Sangamo slashes time to market for Fabry gene therapy
Oct 22, 2024 12:57pm
